Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06344416 · ClinicalTrials.gov registry record · NA
Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
A NA study of Any Solid Oral Medication, sponsored by Dosentrx.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT06344416: Recruiting NA study of Any Solid Oral Medication, sponsored by Dosentrx.
NCT06344416 is a NA study of Any Solid Oral Medication that is actively recruiting participants, run by Dosentrx. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06344416, a NA study of Any Solid Oral Medication, is actively recruiting participants, sponsored by Dosentrx.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group.
Conditions Studied
Interventions
- DEVICE Use of ReX to dispense and monitor solid oral medication therapy.
Study Locations (4)
Minnesota
- Allina - Minneapolis
Texas
- Texas Oncology - Austin
Virginia
- Virginia Cancer Center - Richmond
Wisconsin
- Lumicera - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-03-30 |
| Est. Completion | 2026-01-30 |
| Phase | NA |
What NCT06344416 shows while recruiting
NCT06344416 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Any Solid Oral Medication appearing as the primary indexed condition, and to 1 intervention - of which Use of ReX to dispense and monitor solid oral medication therapy. is the first listed.
NCT06344416 reports a single indexed study location in Minnesota, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT06344416 about?
NCT06344416 is a clinical study titled "Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform". Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on r...
What is the current status of trial NCT06344416?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-03-30. Estimated completion is 2026-01-30.
What conditions does trial NCT06344416 study?
This clinical trial studies the following conditions: Any Solid Oral Medication.
What interventions are being tested in trial NCT06344416?
The interventions under investigation include: Use of ReX to dispense and monitor solid oral medication therapy. (DEVICE).
Who is sponsoring clinical trial NCT06344416?
This trial is sponsored by Dosentrx, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06344416 being conducted?
This trial has 4 study locations across Minnesota, Texas, Virginia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06344416's enrollment target sits among peer trials
200 506th of 2000 higher than 1,435 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI